-
Inventory, common immunodiagnostic tumor markers
Time of Update: 2022-09-14
This antigen is present in the pancreas, gallbladder, liver, intestine and other tissues of the embryonic fetus, and the content in normal human tissues is very low; In the serum of patients with gastrointestinal malignant tumors, especially pancreatic cancer and gallbladder cancer, the content of cancer antigen 19-9 is significantly increased, but the early diagnosis value is not large, mainly as an indicator of disease monitoring and predicting recurrence.
-
Cancer Discov: The mechanism of resistance to alkylated drugs in small cell lung cancer was discovered
Time of Update: 2022-09-14
In previous work, the scientists found that a protein called RNF113A is associated with the ability of cancer cells to repair alkylated damage, a pattern of attack by common chemotherapy drugs.
-
"Friends into Love" is coming! The first oncologist medical humanities slow variety show was launched
Time of Update: 2022-09-14
"Patient-centric" is increasingly becoming one of the standards by which today's healthcare is measured. How to let patients get more care and respect in the treatment process has become an important
-
【Cell Sub-journal】The latest review study of Professor Fang Jingyuan's team of Shanghai Jiaotong University on the prevention and treatment targets of colorectal cancer
Time of Update: 2022-09-14
Recently, Professor Fang Jingyuan's team from Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine published a latest review in Trends in Microbiology, summarizing the biological characteristics and regulatory mechanisms of the development of Clostridium nucleated bacterium in colorectal cancer (CRC), and using Clostridium nucleated as a marker for early warning and prognosis prediction of CRC.
-
Investigative Radiology: Spatial prediction of TACE postoperative drug dose based on cone beam CT scan
Time of Update: 2022-09-14
Doxorubicin levels in tumor specimens were measured by high performance liquid chromatography and correlated with DEB iodine content measured using the embolization treatment planning software based on prototype cone beam CT.
-
Tumor Biology: (13) Invasion and metastasis of tumors
Time of Update: 2022-09-14
6 The key role of extracellular proteasesEMT represents the replication biological process by which cancer cells acquire the ability to invade and motility, which includes a number of important effector molecules, the most important of which is matrix metalloproteinase (MMP).
-
Braz J Otorhinolaryngol: A cell kinetic marker for squamous cell carcinoma and basal cell carcinoma of the skin of the head and neck
Time of Update: 2022-09-14
The objective of this study was to study the proliferative markers ki67, MCM2 and dionyl proteins in head and neck cutaneous basal cell carcinoma and squamous cell carcinoma.
-
Advances in tumor immunotherapy research targeting TIGIT
Time of Update: 2022-09-14
In clinical development, the FcγR binding region of anti-TIGIT antibodies is active in some molecules and inactivated in others.
In clinical development, the FcγR binding region of anti-TIGIT antibodies is active in some molecules and inactivated in others.
-
Exp Dermatol : Dermatometric features of basal cell carcinoma similar to melanoma
Time of Update: 2022-09-14
The objective of this study was to compare atypical non-facial MMS with atypical basal cell carcinoma characteristics with at least one basal cell carcinoma feature in selected cohorts with melanocyte characteristics to identify dermoscopic features to develop scores that would help with differential diagnosis.
-
2022 IMS focuses on cutting-edge progress, explores precise diagnosis and treatment, and opens a new chapter in RRMM treatment with new therapies
Time of Update: 2022-09-09
Risk Stratification: Chinese Evidence Added to Poor Prognosis of 1q21+, R2-ISS Supported by Real-World StudiesMM is still an incurable and highly heterogeneous disease, and the survival outcomes of patients are affected by many factors, and there are often large differences .
-
【STTT】Central South University team developed a new FASN inhibitor for the treatment of various tumors!
Time of Update: 2022-09-09
Recommended · Live/EventAugust 31st 14:00-17:30 GuangzhouThe 2nd Clinical Application Salon of New Diagnostic TechnologyScan the code to participate for freeSeptember 15-16 09:00-17:30 ChongqingThe First Southwest Single Cell Omics Technology Application ForumScan the code to participate for freeThis article is original from Translational Medicine Network, please indicate the source for reprinting Author: TMZHIIntroduction: Fatty acid synthase (FASN) is a key enzyme in regulating the de novo fatty acid synthesis pathway.
-
How to accurately diagnose and treat sellar tumors?
Time of Update: 2022-09-09
*For medical professional reading reference onlyAccurate preoperative diagnosis of hemangioblastoma in the sellar region is conducive to the selection of appropriate treatment plans and to improve the prognosis of patients .
-
These two inherited gene mutations increase the risk of 7 types of cancer!
Time of Update: 2022-09-09
They had 14 different types of cancer (biliary tract, breast, cervical, colorectal, endometrial, esophageal, stomach, liver, lung, lymphoma, ovarian, pancreatic, prostate and kidney cancers) ) or one or more of them .
-
Youyoung, a good doctor, gave a speech on the whole process management of advanced colorectal cancer - a heavy hit in South China
Time of Update: 2022-09-09
Figure 1 Speech by the chairman of the conferenceThe first link: Academic Express - Emphasis on three-line sequence, optimizing treatment decision-makingProfessor Shi Min from Nanfang Hospital of Southern Medical University presided over the academic express session, and Professor Chen Dongliang from Sun Yat-sen University Cancer Center brought an academic sharing on the theme of "Optimization of Third-Line Chemotherapy for Advanced Colorectal Cancer" .
-
Spotlight on Serological Markers to Explore Correlations Between Obesity and Prostate Cancer Risk
Time of Update: 2022-09-09
The researchers first investigated the relationship between obesity index (BMI) and serological markers, such as sex steroids, IGF-1 and its binding protein IGFBPs, and then their effect on obesity-related prostate cancer risk .
-
IMS 2022 Express is the first to demonstrate that prolonged KRd therapy is superior to lenalidomide monotherapy for maintenance of PFS after MM autotransplantation
Time of Update: 2022-09-09
Research methodsThis international open-label phase 3 randomized trial enrolled newly diagnosed MM patients who received ≤12 months of induction therapy followed by a single ASCT and achieved at least stable disease after 100 days .
-
【Cell Discovery】Qin Wenxin's team at Shanghai Jiaotong University proposed a new treatment strategy for hepatocellular carcinoma: EGFR blockade combined with cabozantinib to improve clinical efficacy
Time of Update: 2022-09-09
The researchers also tested the combined effects of cabotinib and two FDA-approved EGFR inhibitors, including gefitinib and afatinib.
The researchers also tested the combined effects of cabotinib and two FDA-approved EGFR inhibitors, including gefitinib and afatinib.
-
【Cell Sub-Journal】New clinical decision?
Time of Update: 2022-09-09
This article is original from Translational Medicine Network, please indicate the source for reprinting Author: TMZHIIntroduction: The emergence of immunotherapy in recent years has greatly changed th
-
Machine learning reveals cellular morphological subtypes and molecular interpretations of LGG
Time of Update: 2022-09-09
Recently, Xiao-Ping Liu of the Department of Biological Systems and Engineering of lawrence Berkeley National Laboratory in the United States has applied machine learning to integrate and verify clinical data and database data, conduct clinical biological evaluation, construct cell morphological background characterization, and apply immunohistochemistry to develop and validate machine learning frameworks for cell morphology measurement subtypes, which are used to discover cell morphological subtypes of LGG related to specific molecular changes, immune microenvironments, prognosis and therapeutic responses.
-
Shengnuo Pharmaceutical siRNA drugs released Phase II clinical data, domestic small nucleic acid drugs or will enter the fast lane
Time of Update: 2022-09-09
Recommended reading: Shengnuo Pharmaceutical skin cancer siRNA drug Phase II clinical realization of 100% complete remission, siRNA technology or will usher in a golden decade?In addition, in recent days, Sunno Pharma also announced that the company is promoting RNAi therapy based on the GalAhead™ delivery platform for the treatment of complement-mediated related diseases.
